## What the “meta-analysis” headline *really* does for XTRAC (even before you model it) I cannot verify—within STRATA’s most recent SEC filings/disclosures—a specific **February 2026 meta-analysis** announcement tied to XTRAC. The latest available disclosures (through mid‑December 2025) do, however, show a clear pattern: management is systematically **stacking clinical validation** alongside **reimbursement catalysts** and **competitive pressure relief** to expand procedure volumes and revenue-per-device over time. ["Multiple new peer-reviewed publications"](0001140361-25-041985|1) ["Investment Highlights"](0001140361-25-045846|1) --- ## 1) Clinical evidence is being used as a commercialization lever—not just “nice-to-have” science STRATA’s disclosures position XTRAC as a clinically established modality (targeted **308nm UVB** excimer) that physicians can deploy under a recurring, procedure-driven model. That matters because the company’s economics are ultimately tied to **utilization** (treatments per device) more than one-time capital sales. ["targeted 308nm ultraviolet light"](0001140361-25-042373|0) ["revenue on a per procedure basis"](0001140361-25-042373|0) Management also emphasizes an expanding body of peer‑reviewed work validating outcomes across autoimmune dermatology use cases (including combination approaches), which is the type of “credibility asset” that can influence physician adoption and payer acceptance over time. ["Multiple new peer-reviewed publications further validating"](0001140361-25-041985|1) --- ## 2) “Hidden” alpha: evidence + reimbursement code expansion is the real flywheel Between the lines, the clinical-efficacy narrative is being paired with what is likely the bigger financial unlock: progress toward **expanded CPT code reimbursement** for inflammatory/auto-immune skin diseases—explicitly framed as potentially **tripling the covered patient population** in the U.S., with expanded codes referenced as being recognized in the **CMS 2026 final PFS rule**. If that path holds, clinical validation becomes a *tool* to accelerate physician behavior and payer behavior into a larger reimbursed pool. ["tripling the covered patient population"](0001140361-25-041985|1) ["CMS 2026 final PFS"](0001140361-25-041985|1) STRATA’s investor materials further lean into the same direction: they describe a “historic CPT code expansion” that could unlock **30M+ covered potential patients**, with new indications expected to become effective **January 2027**, and also flag potential **temporary G‑codes** as a nearer-term bridge into 2026 revenue opportunities (if provisioned). ["unlock >30 million in covered potential patients"](0001140361-25-045846|1) ["effective 1/1/27"](0001140361-25-045846|1) ["Temporary G-codes"](0001140361-25-045846|1) --- ## 3) The business model makes incremental proof disproportionately valuable STRATA explicitly runs XTRAC primarily as a **recurring revenue** model, charging per-procedure (or fixed-period arrangements with caps). That structure means incremental confidence in efficacy doesn’t just “support the brand”—it can translate into (i) more starts, (ii) higher completion of multi-treatment regimens, and (iii) better retention of clinics on the platform. ["recurring revenue business model"](0001140361-25-042373|0) ["generate revenue on a per procedure basis"](0001140361-25-042373|0) The company also discloses that procedure volumes depend on marketing and awareness—and that they intend to increase direct-to-patient advertising to drive demand back through physician partners. In that context, high-level clinical messaging (like a meta-analysis headline) is not just “PR”; it’s fuel for demand-gen. ["dependent upon building market acceptance"](0001140361-25-042373|0) ["continue to increase our direct-to-patient program"](0001140361-25-042373|0) --- ## 4) A second, quieter tailwind: competition dynamics and clinic recapture In the most recent corporate update, STRATA claims it has been **recapturing partner clinics** previously lost to a competitor (LaserOptek) and highlights positive developments in ongoing litigation—signaling that competitive intensity may be easing *at the margin*. If true, stronger clinical messaging can be particularly effective during “switch-back” windows when clinics are re-evaluating platforms and reimbursement certainty. ["Recapturing of dozens of partner clinics"](0001140361-25-041985|1) ["Positive developments in the ongoing lawsuit"](0001140361-25-041985|1) --- ### Bottom line (impactful read-through) The “308nm excimer efficacy” narrative is best viewed as part of STRATA’s broader playbook: **convert scientific validation into reimbursement expansion and utilization growth** under a recurring procedure model—while competitive friction potentially declines. The alpha is that these disclosures imply a pathway where the upside is less about selling more boxes and more about **re‑rating the earnings power per device** as coverage broadens and demand-gen improves. ["fee-per-use-based recurring procedures"](0001140361-25-045846|1) ["Expand reimbursed indications for use"](0001140361-25-045846|1) ["Average gross billings per device of $5,981 increased 8.5%"](0001140361-25-041985|1)

## What the “meta-analysis” headline *really* does for XTRAC (even before you model it) I cannot verify—within STRATA’s most recent SEC filings/disclosures—a specific **February 2026 meta-analysis** announcement tied to XTRAC. The latest available disclosures (through mid‑December 2025) do, however, show a clear pattern: management is systematically **stacking clinical validation** alongside **reimbursement catalysts** and **competitive pressure relief** to expand procedure volumes and revenue-per-device over time. ["Multiple new peer-reviewed publications"](0001140361-25-041985|1) ["Investment Highlights"](0001140361-25-045846|1) --- ## 1) Clinical evidence is being used as a commercialization lever—not just “nice-to-have” science STRATA’s disclosures position XTRAC as a clinically established modality (targeted **308nm UVB** excimer) that physicians can deploy under a recurring, procedure-driven model. That matters because the company’s economics are ultimately tied to **utilization** (treatments per device) more than one-time capital sales. ["targeted 308nm ultraviolet light"](0001140361-25-042373|0) ["revenue on a per procedure basis"](0001140361-25-042373|0) Management also emphasizes an expanding body of peer‑reviewed work validating outcomes across autoimmune dermatology use cases (including combination approaches), which is the type of “credibility asset” that can influence physician adoption and payer acceptance over time. ["Multiple new peer-reviewed publications further validating"](0001140361-25-041985|1) --- ## 2) “Hidden” alpha: evidence + reimbursement code expansion is the real flywheel Between the lines, the clinical-efficacy narrative is being paired with what is likely the bigger financial unlock: progress toward **expanded CPT code reimbursement** for inflammatory/auto-immune skin diseases—explicitly framed as potentially **tripling the covered patient population** in the U.S., with expanded codes referenced as being recognized in the **CMS 2026 final PFS rule**. If that path holds, clinical validation becomes a *tool* to accelerate physician behavior and payer behavior into a larger reimbursed pool. ["tripling the covered patient population"](0001140361-25-041985|1) ["CMS 2026 final PFS"](0001140361-25-041985|1) STRATA’s investor materials further lean into the same direction: they describe a “historic CPT code expansion” that could unlock **30M+ covered potential patients**, with new indications expected to become effective **January 2027**, and also flag potential **temporary G‑codes** as a nearer-term bridge into 2026 revenue opportunities (if provisioned). ["unlock >30 million in covered potential patients"](0001140361-25-045846|1) ["effective 1/1/27"](0001140361-25-045846|1) ["Temporary G-codes"](0001140361-25-045846|1) --- ## 3) The business model makes incremental proof disproportionately valuable STRATA explicitly runs XTRAC primarily as a **recurring revenue** model, charging per-procedure (or fixed-period arrangements with caps). That structure means incremental confidence in efficacy doesn’t just “support the brand”—it can translate into (i) more starts, (ii) higher completion of multi-treatment regimens, and (iii) better retention of clinics on the platform. ["recurring revenue business model"](0001140361-25-042373|0) ["generate revenue on a per procedure basis"](0001140361-25-042373|0) The company also discloses that procedure volumes depend on marketing and awareness—and that they intend to increase direct-to-patient advertising to drive demand back through physician partners. In that context, high-level clinical messaging (like a meta-analysis headline) is not just “PR”; it’s fuel for demand-gen. ["dependent upon building market acceptance"](0001140361-25-042373|0) ["continue to increase our direct-to-patient program"](0001140361-25-042373|0) --- ## 4) A second, quieter tailwind: competition dynamics and clinic recapture In the most recent corporate update, STRATA claims it has been **recapturing partner clinics** previously lost to a competitor (LaserOptek) and highlights positive developments in ongoing litigation—signaling that competitive intensity may be easing *at the margin*. If true, stronger clinical messaging can be particularly effective during “switch-back” windows when clinics are re-evaluating platforms and reimbursement certainty. ["Recapturing of dozens of partner clinics"](0001140361-25-041985|1) ["Positive developments in the ongoing lawsuit"](0001140361-25-041985|1) --- ### Bottom line (impactful read-through) The “308nm excimer efficacy” narrative is best viewed as part of STRATA’s broader playbook: **convert scientific validation into reimbursement expansion and utilization growth** under a recurring procedure model—while competitive friction potentially declines. The alpha is that these disclosures imply a pathway where the upside is less about selling more boxes and more about **re‑rating the earnings power per device** as coverage broadens and demand-gen improves. ["fee-per-use-based recurring procedures"](0001140361-25-045846|1) ["Expand reimbursed indications for use"](0001140361-25-045846|1) ["Average gross billings per device of $5,981 increased 8.5%"](0001140361-25-041985|1)